Entera Bio Ltd.

ENTX

Entera Bio Ltd.

ENTX

Insider Sentiment (TTM):

Last Purchase:2026-03-09Last Sale:-Shares Purchased (TTM):101,500Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:7,849,156Shares Outstanding:47,756,409Institutional Ownership Pct.:16.44%

Earnings Market Reaction:

Filing Date:2026-08-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	11	4	7	9	11	13	9	7	9	9	11	8
Accounts Receivable Net Current	-	-	0	0	0	0	0	0	0	-	0	0
Restricted Cash Current	-	-	8	-	-	-	0	-	-	-	-	-
Restricted Cash	7	8	-	8	8	8	-	-	-	-	-	-
Prepaid Expense And Other Assets Current	0	1	0	0	0	1	0	0	0	1	0	0
Assets Current	19	12	15	17	19	21	9	7	10	10	11	8
Assets Noncurrent
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Income Tax Assets Net	-	-	-	-	-	-	0	0	0	0	0	0
Deposits Assets Noncurrent	0	0	0	0	0	0	0	-	-	-	0	-
Defined Benefit Plan Assets For Plan Benefits Nonc…	0	0	0	0	0	0	0	0	0	0	0	0
Assets Noncurrent	1	1	1	0	0	0	0	0	0	0	1	1
Assets	19	13	16	17	20	22	9	8	10	10	12	9
Liabilities And Stockhold…
Liabilities
Liabilities Current
Accounts Payable Current	1	0	0	0	0	0	0	0	0	0	0	1
Accrued Liabilities And Other Liabilities	1	1	2	1	1	1	1	1	1	1	1	1
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	2	2	2	2	2	2	1	1	1	1	1	2
Liabilities Noncurrent
Operating Lease Liability Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Other Liabilities Noncurrent	-	-	0	-	-	-	0	-	-	-	-	-
Other Long Term Debt Noncurrent	0	1	-	1	1	1	-	-	-	-	-	-
Postemployment Benefits Liability Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Noncurrent	10	1	1	1	1	1	0	0	0	0	0	0
Liabilities	12	2	3	2	2	2	1	1	2	1	1	2
Stockholders Equity Numbe…
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	-
Additional Paid In Capital Common Stock	143	140	138	138	136	136	122	118	117	115	115	109
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	0	0	0	0	0	0	0	0	0
Retained Earnings Accumulated Deficit	-136	-129	-125	-122	-119	-116	-114	-112	-109	-106	-104	-102
Stockholders Equity	7	11	13	15	17	19	8	6	9	9	10	6
Liabilities And Stockholders Equity	19	13	16	17	20	22	9	8	10	10	12	9
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	140	140	140	140	140	140	140	140	140	140	140	140
Common Stock Shares Issued	49	47	46	46	45	45	39	37	36	36	35	29
Shares Outstanding	49	47	46	46	45	45	39	37	36	36	35	29

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	3.85%	25.38%	57.69%	-	-	-	-	-	-
2025	-14.19%	-7.91%	-13.49%	6.04%	0.00%	21.98%	13.27%	11.50%	8.85%
2024	-	-	-	-	-	-	2.29%	16.00%	6.29%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	8.98	7.93	6.94	10.83	10.47	13.07	7.63	6.61	7.41	8.70	10.32	3.95
Quick Ratio	8.76	7.57	6.76	10.57	10.23	12.75	7.47	6.26	7.04	8.20	10.10	3.74
Working Capital	16.79M	10.92M	13.10M	15.44M	17.47M	19.60M	7.80M	6.23M	8.30M	8.63M	10.17M	5.99M
Leverage & Debt
Debt to Equity	1.68	0.23	0.22	0.14	0.14	0.11	0.16	0.20	0.18	0.16	0.13	0.37
Debt Ratio	0.63	0.19	0.18	0.12	0.12	0.10	0.14	0.17	0.15	0.13	0.12	0.27
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.01	0.01	0.01	0.02	0.01	0.01	0.00	0.00	0.00
Days Sales Outstanding TTM	-	-	-	-	-	206.23	254.09	154.85	275.35	-	-	-
Receivables Turnover TTM	-	-	-	-	-	1.77	1.44	2.36	1.33	-	-	-
Per Share Metrics
Diluted EPS TTM	0.34	0.26	0.25	0.23	0.23	0.23	0.25	0.24	0.23	0.24	0.31	0.34
Free Cash Flow Per Share TTM	-0.18	-0.19	-0.16	-0.12	-0.11	-0.15	-0.18	-0.21	-0.20	-0.21	-0.25	-0.23
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	4.04%	-	-	-	-	-	-
Operating Profit Margin TTM	-	-	27,450.00%	8,729.03%	6,378.92%	4,522.87%	5,295.58%	9,304.04%	15,045.61%	-	-	71,400.00%
Net Profit Margin TTM	-	-	27,235.71%	8,694.35%	6,386.75%	4,525.11%	5,271.27%	9,270.71%	14,975.44%	-	-	70,921.43%
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-100.00%	-76.80%	25.25%	191.23%	-	-	607.14%	159.09%	-100.00%	-100.00%	-88.33%
Net Income Growth (1Y)	60.66%	22.65%	19.89%	17.47%	24.20%	15.78%	7.33%	-7.56%	-19.60%	-24.06%	-31.99%	-1.07%
EPS Growth (1Y)	49.15%	11.41%	-2.28%	-6.10%	-1.64%	-1.95%	-17.30%	-29.25%	-37.54%	-40.44%	-32.46%	-1.08%
Valuation Metrics
P/E TTM	5.24	4.28	7.83	8.39	8.39	7.31	8.37	7.79	8.00	7.04	1.96	2.10
P/B TTM	12.29	4.96	6.84	5.93	5.16	3.81	9.88	11.09	8.00	6.92	1.68	3.35
P/S TTM	-	-	2,133.59	729.13	536.08	330.68	440.99	722.47	1,197.30	-	-	1,492.15
Market Cap	89.30M	53.01M	89.61M	90.41M	88.99M	73.74M	79.82M	71.52M	68.25M	61.35M	17.40M	20.89M
Enterprise Value	70.77M	40.99M	74.64M	73.72M	70.04M	61.17M	71.16M	64.53M	59.11M	52.10M	6.32M	13.21M
Calculated Values
Free Cash Flow TTM	-9.28M	-9.16M	-7.48M	-5.68M	-5.28M	-6.37M	-6.82M	-7.97M	-7.34M	-7.57M	-7.33M	-6.72M
Net Debt	-18.53M	-12.02M	-14.97M	-16.69M	-18.95M	-12.57M	-8.66M	-6.99M	-9.13M	-9.25M	-11.09M	-7.68M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-09Purchase

Owner: Germano, Geno J

Title: -

Shares: 20,000

Price/Share: $1.30

Value: $26,000.00

Shares Owned: 40,000

Relationship: Director

Ownership: Direct

2026-03-05Purchase

Owner: Ellis, Sean

Title: -

Shares: 10,000

Price/Share: $1.23

Value: $12,300.00

Shares Owned: 188,098

Relationship: Director

Ownership: Direct

2026-02-12Purchase

Owner: Rubin, Steven D

Title: -

Shares: 5,000

Price/Share: $1.49

Value: $7,450.00

Shares Owned: 15,000

Relationship: Director

Ownership: Direct

2026-02-10Purchase

Owner: Taitel, Haya

Title: -

Shares: 7,500

Price/Share: $1.48

Value: $11,100.00

Shares Owned: -

Relationship: Director

Ownership: Direct

2026-02-10Purchase

Owner: Germano, Geno J

Title: -

Shares: 20,000

Price/Share: $1.49

Value: $29,800.00

Shares Owned: -

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-09	Germano, Geno J	Director	-	Direct	Purchase	20,000	1.30	$26,000.00	40,000	4
2026-03-05	Ellis, Sean	Director	-	Direct	Purchase	10,000	1.23	$12,300.00	188,098	4
2026-02-12	Rubin, Steven D	Director	-	Direct	Purchase	5,000	1.49	$7,450.00	15,000	4
2026-02-10	Taitel, Haya	Director	-	Direct	Purchase	7,500	1.48	$11,100.00	-	4
2026-02-10	Germano, Geno J	Director	-	Direct	Purchase	20,000	1.49	$29,800.00	-	4
2026-02-09	Ellis, Sean	Director	-	Direct	Purchase	18,000	1.24	$22,320.00	178,098	4
2026-02-09	Rubin, Steven D	Director	-	Direct	Purchase	10,000	1.20	$12,000.00	10,000	4
2025-12-29	Toledano, Miranda Jayne	Director,Officer	Chief Executive Officer	Direct	Purchase	11,000	1.81	$19,910.00	426,575	4
2024-01-12	Taitel, Haya	Director	-	Direct	Purchase	9,500	0.99	$9,405.00	35,115	4
2024-01-10	Taitel, Haya	Director	-	Direct	Purchase	7,615	0.77	$5,863.55	25,615	4
2023-12-22	Toledano, Miranda Jayne	Director,Officer	Chief Executive Officer	Direct	Purchase	23,952	0.71	$17,005.92	110,752	4
2023-12-22	Lieberman, Gerald M	Director	-	Direct	Purchase	23,952	0.71	$17,005.92	226,961	4
2023-08-22	Taitel, Haya	Director	-	Direct	Purchase	18,000	0.62	$11,160.00	18,000	4
2023-08-21	Ellis, Sean	Director	-	Direct	Purchase	40,000	0.60	$24,000.00	102,100	4
2023-08-21	Lieberman, Gerald M	Director	-	Direct	Purchase	20,000	0.59	$11,800.00	214,209	4
2023-04-04	Toledano, Miranda Jayne	Director,Officer	Chief Executive Officer	Direct	Purchase	30,000	1.01	$30,300.00	86,800	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

16.44%

Inst. Shares: 7,849,156

Shares Outstanding: 47,756,409

2025-12-31

20.16%

Inst. Shares: 9,311,864

Shares Outstanding: 46,191,067

2025-09-30

19.23%

Inst. Shares: 9,053,874

Shares Outstanding: 47,089,814

2025-06-30

21.50%

Inst. Shares: 10,070,300

Shares Outstanding: 46,836,700

2025-03-31

23.57%

Inst. Shares: 10,222,258

Shares Outstanding: 43,377,391

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	7,849,156	47,756,409	16.44%
2025-12-31	9,311,864	46,191,067	20.16%
2025-09-30	9,053,874	47,089,814	19.23%
2025-06-30	10,070,300	46,836,700	21.50%
2025-03-31	10,222,258	43,377,391	23.57%
2024-12-31	7,510,999	37,650,179	19.95%
2024-09-30	5,310,741	37,644,612	14.11%
2024-06-30	5,280,502	37,090,160	14.24%
2024-03-31	4,162,465	36,735,429	11.33%
2023-12-31	4,005,246	29,007,794	13.81%
2023-09-30	2,555,626	28,813,952	8.87%
2023-06-30	2,526,691	28,812,375	8.77%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Entera Bio Ltd. (ENTX) — SEC Financial Statements & Analysis

Entera Bio Ltd. (ENTX) is a biological products, (no diagnostic substances) company, incorporated in L3. Entera Bio Ltd. trades on Nasdaq as: ENTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Entera Bio Ltd. reported a -100.00% year-over-year revenue growth, a Gross Profit Margin of 4.04% (TTM), a Debt-to-Equity ratio of 1.68x, a Price-to-Sales (P/S) ratio of 2133.59x (TTM), a Price-to-Book (P/B) ratio of 12.29x (TTM), at a market cap of $89.30M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Gross Profit Margin TTM: 4.04%
Debt To Equity: 1.68x
P/S TTM: 2133.59x
P/B TTM: 12.29x
Market Cap: $89.30M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Entera Bio Ltd. in?

Entera Bio Ltd. (ENTX) operates in the Biological Products, (No Diagnostic Substances) industry.

What is ENTX's market cap?

Entera Bio Ltd. (ENTX) has a market capitalization of $89.30M as of 2026-06-30.

What is ENTX's P/E ratio?

Entera Bio Ltd. (ENTX)'s trailing twelve month P/E ratio is 5.24x as of 2026-06-30.

What exchange does ENTX trade on?

Entera Bio Ltd. (ENTX) trades on the Nasdaq.

Where is Entera Bio Ltd. incorporated?

Entera Bio Ltd. is incorporated in Israel.

Entera Bio Ltd.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Entera Bio Ltd. (ENTX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

Entera Bio Ltd. (ENTX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.